AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05363956
Drug: salvadora
RxNorm normalized name: SALVADORA PERSICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
Trial: NCT04640376
Drug: Panadol 500 MG Oral Tablet X1
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet masked in capsule
Trial: NCT04640376
Drug: Panadol 500 MG Oral Tablet X2
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet masked in capsule
Trial: NCT04640376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy treatment
Trial: NCT06154720
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the woman had a repaired episiotomy following uncomplicated vaginal birth at 37 weeks or greater with no indication for ongoing antibiotics in the postpartum period. The patients were randomized to receive a co-amoxiclav 625mg (study group) tabs twice daily for 3 days after delivery or no antibiotic arm (control group).
Trial: NCT04808414
Drug: QPX9003 for IV Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic
Trial: NCT04808414
Drug: Placebo for IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT06345729
Drug: MK-1084
RxNorm normalized name: vitamin MK 7
DrugBank: MK-5108 (DB12556)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT06323395
Drug: Vizol S LIPID BALANCE eye drops
RxNorm normalized name: Luden's Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop 4 times a day
Trial: NCT06323395
Drug: ophthalmic saline eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop 4 times a day
Trial: NCT05132790
Drug: SHR-1316 at a dose 20mg/kg q3w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin
Trial: NCT05132790
Drug: SHR6390 at a dose of 150mg orally, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT
Trial: NCT06323213
Drug: 610
RxNorm normalized name: AY-6108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 610 subcutaneously injection.
Trial: NCT06323213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneously injection.
Trial: NCT05122780
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.e. atorvastatin; dosages titrated on the patient's clinical characteristics
Trial: NCT05122780
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.e. bisoprolol; dosages titrated on blood pressure, ECG, heart rate
Trial: NCT05122780
Drug: ACEi/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.e. ramipril; dosages titrated on blood pressure, ECG, heart rate
Trial: NCT05122780
Drug: CCB
RxNorm normalized name: olive/homosal/ccb/coco oil/alm TOPICAL OIL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.e. diltiazem; dosages titrated on blood pressure, ECG, heart rate
Trial: NCT05474755
Drug: GP681 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2X20mg tablets taken orally
Trial: NCT05474755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching GP681 40mg
Trial: NCT05712837
Drug: 25% TRICHLOROACETIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
Trial: NCT00954200
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 10mg/kg syrup, single dose vs placebo
Trial: NCT00954200
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/kg syrup - single dose
Trial: NCT05635877
Drug: Placebo Comparator: Placebo Comparator:normal saline(0.9%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
Trial: NCT04893187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo.
Trial: NCT05223166
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
Trial: NCT05122377
Drug: 3M GnRHa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
Trial: NCT03885245
Drug: L-ctirulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
Trial: NCT04551768
Drug: 50 mg/mL Virazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
Trial: NCT04551768
Drug: 100 mg/mL Virazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
Trial: NCT04750278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID
Trial: NCT00001070
Drug: Oral Vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05118763
Drug: INNA-051
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid for intranasal administration
Trial: NCT05357755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally as delayed release tablets.
Trial: NCT04421352
Drug: CS1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned.
Trial: NCT05912075
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy
Trial: NCT05912075
Drug: FOLFOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy
Trial: NCT05912075
Drug: CAPOX
RxNorm normalized name: Capecitabine and Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
Trial: NCT05853367
Drug: MK-0472
RxNorm normalized name: vitamin MK 7
DrugBank: MK-0752 (DB12852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT05853367
Drug: MK-1084
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT05667818
Drug: Amlodipine besylate tablets (trade name: Norfloxacin ®）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
Trial: NCT05119686
Drug: AR882 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid Oral Capsule
Trial: NCT05119686
Drug: AR882 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid Oral Capsule
Trial: NCT05119686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Solid Oral Capsule Placebo
Trial: NCT04783870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06015568
Drug: MCLA-129: 1500mg or 2000mg IV Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs
Trial: NCT05193968
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min
Trial: NCT05193968
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
Trial: NCT06467539
Drug: DAOIB plus AO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, for 24 weeks
Trial: NCT06467539
Drug: DAOIB plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, for 24 weeks
Trial: NCT05987332
Drug: IDE196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed orally, twice daily
Trial: NCT05964920
Drug: Saline + Resistance exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.
Trial: NCT05964920
Drug: Testosterone Undecanoate + Resistance exercise training
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.
Trial: NCT06345599
Drug: Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF treatment: GM-CSF 200μg was started on the day of radiotherapy, and was subcutaneously injected daily for 7 consecutive days; d1-d7 Cadumilimab: use 375mg of cadumilimab within one week after radiotherapy
Trial: NCT06001853
Drug: DSMO Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 6 months, patients randomized to Arm B: DMSO will be unblinded and re-assigned to Arm A: treatment then be followed for 12 months.
Trial: NCT05768529
Drug: U16
RxNorm normalized name: LU16 (ISBT symbol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.
Trial: NCT06011980
Drug: Growth Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: growth inhibitors for 250-500μg/h, ivgtt. for 5 days
Trial: NCT05682599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06041152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of placebo separated by one week.
Trial: NCT05411991
Drug: Intravenous bumetanide TID
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR \>45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR \<30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), a dose of 4 mg TID is used.
Trial: NCT05411991
Drug: Oral chlorthalidone OD
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In case of hypernatremia (\>145 mmol/L) or low eGFR (\<30 mL/min/1.73m²), oral chlorthalidone 50 mg OD is added to the diuretic treatment. At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), oral chlorthalidone is provided at a dose of 100 mg OD. Chlorthalidone is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L.
Trial: NCT04687540
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are under influence of tocilizumab since the effect of the drug will last for 4 weeks. Participants will be infused with saline at study visit 2 (study day 21). Placebo to tocilizumab will be saline (NaCl 0.9%) as tocilizumab is a colorless solution and has to be diluted with NaCl 0.9% prior to administration
Trial: NCT05223803
Drug: Systemic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All systemic therapy is provided as best prescribed for patient per their medical oncologist.
Trial: NCT05327595
Drug: LY3549492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05327595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05961189
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care, 5 days of drug per manufacturer's instructions.
Trial: NCT06551298
Drug: Atorvastatin Calcium 20Mg Tab
RxNorm normalized name: ATORVASTATIN CALCIUM 20MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin Calcium Tablets (20mg, qn)+Low Fat Diet
Trial: NCT05186051
Drug: ZYIL1 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLRP3 inflammasome inhibitor
Trial: NCT06269393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group: 10 mg/kg of placebo on Day 1, followed by 20 mg/kg, q3W of placebo for the following 3 infusions.10 mg/kg of IBI311 at Week 12, followed by 20 mg/kg, q3W of IBI311 for the remaining 3 infusions.
Trial: NCT06269393
Drug: IBI311
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI311 group: 10 mg/kg of IBI311 on Day 1, followed by 20 mg/kg, q3W of IBI311 for the remaining 7 infusions; .
Trial: NCT03585946
Drug: Site specific standard of care comparison
RxNorm normalized name: SOLO SITE WOUND CARE GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
Trial: NCT06372314
Drug: Total parenteral nutrition (TPN): this is total nutrition provided by central vein.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isoleucine, leucine, valine and tryptophan intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
Trial: NCT05249387
Drug: A-967079 and BAM8-22 application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Trial: NCT05249387
Drug: A-967079 and BAM8-22 application after 5 minutes.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules
Trial: NCT05249387
Drug: A-967079 application.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm
Trial: NCT05249387
Drug: Vehicle and BAM8-22 application.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Trial: NCT05566626
Drug: Mydriacyl Ophthalmic Product
RxNorm normalized name: Mydriacyl Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mydriatic drops before retinoscopy
Trial: NCT05711017
Drug: Huashibaidu granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the Huashibaidu group will receive Huashibaidu granule two times a day for five consecutive days (day 1\~5).
Trial: NCT06267820
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: analgesia
Trial: NCT05576961
Drug: RX-af01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment： vancomycin: 125mg po, tid, D-6 to D-3 RX-af01: 2 capsules, bid, po, D-2 to D0 Treatment (Every 3 weeks) RX-af01: 1 capsule, bid, po, every day Toripalimab: 240mg, ivdrip, D1, every 3 weeks.
Trial: NCT05576961
Drug: Mixed bacteria
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
Trial: NCT06066255
Drug: Thymoglobulin Injectable Product
RxNorm normalized name: Thymoglobulin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous injection of thymoglobulin
Trial: NCT05711017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the placebo group will receive placebo two times a day for five consecutive days (day 1\~5).
Trial: NCT03613792
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opioid analgesic
Trial: NCT03613792
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Opioid analgesic
Trial: NCT05098366
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mL/kg (max 1000mL) normal saline bolus plus a normal saline flush
Trial: NCT05649696
Drug: Recombinant Staphylokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Trial: NCT05649696
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of normal saline is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Trial: NCT06378060
Drug: Modified transplantation system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA
Trial: NCT05057858
Drug: co-formulated 300 mg TDF/ 200mg FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
Trial: NCT05013632
Drug: Antiviral Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral medications indicated for the treatment of mild to severe COVID-19
Trial: NCT06302049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT05341050
Drug: TKI
RxNorm normalized name: Catkin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: halve dose of 2G-TKI for 12 months and then withdrawal for 12 months
Trial: NCT04948827
Drug: SBP-9330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBP-9330 oral capsules
Trial: NCT04948827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules
Trial: NCT04611139
Drug: SP-2577
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral doses
Trial: NCT05208827
Drug: The placebo(not contain vitamin D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills that looked, colored and tasted like vitamin D in the control group, but contained only starch and vegetable oil and no vitamin D.
Trial: NCT05982197
Drug: Standard Preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation for prevention radiation induced oral mucositis
Trial: NCT05028829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo
Trial: NCT05543928
Drug: CTAP101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
Trial: NCT05543928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo